Hutchison Chi-Med to trial HMPL-689 in China

By

Sharecast News | 29 Aug, 2017

11:15 07/10/24

  • 317.00
  • 2.26%7.00
  • Max: 328.00
  • Min: 316.00
  • Volume: 283,028
  • MM 200 : n/a

Hutchison China MediTech announced on Tuesday that it has initiated a Phase I clinical trial of HMPL‑689 in China.

Last news

Solid State wins 'two significant contracts' in US defence sector
hVIVO upbeat on positive human challenge trial results with client
FD Technologies agrees £230m sale of First Derivative business
Consumer veteran Shapland to replace Boddy as Hollywood Bowl chair
AstraZeneca enters into exclusive license agreement with CSPC